HRP20161171T1 - AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA - Google Patents

AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA Download PDF

Info

Publication number
HRP20161171T1
HRP20161171T1 HRP20161171TT HRP20161171T HRP20161171T1 HR P20161171 T1 HRP20161171 T1 HR P20161171T1 HR P20161171T T HRP20161171T T HR P20161171TT HR P20161171 T HRP20161171 T HR P20161171T HR P20161171 T1 HRP20161171 T1 HR P20161171T1
Authority
HR
Croatia
Prior art keywords
amino
thiazol
imino
ethoxy
oxo
Prior art date
Application number
HRP20161171TT
Other languages
English (en)
Croatian (hr)
Inventor
Burkhard Klenke
Irith WIEGAND
Guido Schiffer
Heike Broetz-Oesterhelt
Samarendra N. Maiti
Jehangir Khan
Andhe REDDY
Zhixiang Yang
Mostafa HENA
Guofeng Jia
Ou LIGONG
Hong Liang
Judy Yip
Chuanjun Gao
Sabiha TAJAMMUL
Rahim Mohammad
Ganguli BISWAJEET
Original Assignee
Aicuris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co. Kg filed Critical Aicuris Gmbh & Co. Kg
Publication of HRP20161171T1 publication Critical patent/HRP20161171T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20161171TT 2012-01-24 2013-01-23 AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA HRP20161171T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
EP13701246.4A EP2806873B1 (en) 2012-01-24 2013-01-23 Amidine substituted beta-lactam compounds, their preparation and use as antibacterial agents

Publications (1)

Publication Number Publication Date
HRP20161171T1 true HRP20161171T1 (hr) 2016-11-04

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161171TT HRP20161171T1 (hr) 2012-01-24 2013-01-23 AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA

Country Status (42)

Country Link
US (2) US9556165B2 (en:Method)
EP (1) EP2806873B1 (en:Method)
JP (1) JP5869701B2 (en:Method)
KR (1) KR102036393B1 (en:Method)
CN (1) CN104203237A (en:Method)
AP (1) AP2014007880A0 (en:Method)
AR (1) AR089796A1 (en:Method)
AU (1) AU2013211575B2 (en:Method)
BR (1) BR112014017968A8 (en:Method)
CA (1) CA2862338C (en:Method)
CL (1) CL2014001956A1 (en:Method)
CO (1) CO7101240A2 (en:Method)
CU (1) CU24273B1 (en:Method)
CY (1) CY1117955T1 (en:Method)
DK (1) DK2806873T3 (en:Method)
EA (1) EA027126B1 (en:Method)
EC (1) ECSP14010249A (en:Method)
ES (1) ES2592403T3 (en:Method)
HR (1) HRP20161171T1 (en:Method)
HU (1) HUE030452T2 (en:Method)
IL (1) IL233805A (en:Method)
IN (1) IN2014MN01640A (en:Method)
LT (1) LT2806873T (en:Method)
MA (1) MA35905B1 (en:Method)
ME (1) ME02532B (en:Method)
MX (1) MX346602B (en:Method)
MY (1) MY173843A (en:Method)
NZ (1) NZ626951A (en:Method)
PE (1) PE20142345A1 (en:Method)
PH (1) PH12014501671B1 (en:Method)
PL (1) PL2806873T3 (en:Method)
PT (1) PT2806873T (en:Method)
RS (1) RS55210B1 (en:Method)
SG (1) SG11201403930XA (en:Method)
SI (1) SI2806873T1 (en:Method)
SM (1) SMT201600354B (en:Method)
TN (1) TN2014000297A1 (en:Method)
TW (1) TWI659953B (en:Method)
UA (1) UA110880C2 (en:Method)
UY (1) UY34585A (en:Method)
WO (1) WO2013110643A1 (en:Method)
ZA (1) ZA201405057B (en:Method)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160326157A1 (en) * 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
CN108137573B (zh) * 2015-09-23 2021-06-11 诺华股份有限公司 单环内酰胺抗生素的盐和固体形式
MA44083A (fr) 2015-12-15 2021-06-02 Merck Sharp & Dohme Composés de biarylmonobactame pour le traitement d'infections bactériennes
KR102408800B1 (ko) * 2016-03-07 2022-06-13 머크 샤프 앤드 돔 코포레이션 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
EP3515926B1 (en) 2016-08-26 2023-10-25 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
AU2017361875A1 (en) 2016-11-18 2019-06-06 Aicuris Gmbh & Co. Kg Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
EP3541382A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
AU2017339587A1 (en) * 2016-12-21 2019-07-04 Aicuris Gmbh & Co. Kg Combination therapy with amidine substituted ß-lactam compounds and ß-lactamase inhibitors for infections with antibiotic resistant bacterial strains
WO2019016066A1 (de) 2017-07-18 2019-01-24 Bayer Cropscience Aktiengesellschaft Substituierte 3-heteroaryloxy-1h-pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe
TW201920163A (zh) 2017-07-28 2019-06-01 德商艾庫里斯抗感染治療有限公司 (2s)‐2‐[[(z)‐[1‐(2‐胺基‐4‐噻唑基)‐2‐[[(3s)‐2,2‐二甲基‐4‐側氧基‐1‐(磺氧)‐3‐吖丁啶基]胺基]‐2‐氧亞乙基]胺基]氧基]‐3‐[4‐[亞胺基[(3r)‐3-哌啶基胺基]甲基]苯氧基]-丙酸之晶型
US11414411B2 (en) 2017-08-02 2022-08-16 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof
SG11202002300QA (en) * 2017-10-02 2020-04-29 Arixa Pharmaceuticals Inc Aztreonam derivatives and uses thereof
CN118496221A (zh) * 2017-10-02 2024-08-16 默沙东有限责任公司 用于治疗细菌感染的苯并二氢吡喃单环β-内酰胺类化合物
WO2019144969A1 (zh) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 用于治疗细菌感染的单环β-内酰胺化合物
WO2020098635A1 (zh) * 2018-11-13 2020-05-22 南京圣和药业股份有限公司 单环内酰胺化合物及其应用
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
US20230295149A1 (en) * 2020-07-16 2023-09-21 Ningxia Academy Of Agriculture And Forestry Sciences Monobactam compounds, their preparation and use as antibacterial agents
EP4007759A4 (en) * 2020-08-06 2024-04-10 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL AGENTS
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
CA3237929A1 (en) * 2021-11-18 2023-05-25 Helen Y. Chen Chromane amidine monobactam antibiotics
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
JPH01290674A (ja) 1988-04-04 1989-11-22 E R Squibb & Sons Inc アゼチジニル誘導体
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
DE60111757T2 (de) * 2000-09-14 2006-04-27 Pantherix Ltd. 3-(Heteroarylacetamido)-2-oxoazetidin-1-sulfonsäure-derivate als antibakterielle Mittel
CA2554333A1 (en) 2004-01-27 2005-08-04 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
EP1978959B1 (en) 2005-09-23 2011-11-09 M's Science Corporation Piperidine and piperazine derivatives
WO2007065288A2 (en) * 2005-12-07 2007-06-14 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
NZ595579A (en) 2006-02-14 2013-03-28 Ihara Chemical Ind Co 5-Difluoromethoxy-4-hydroxymethyl-1-methyl-3-trifluoromethyl-pyrazole / (5-(difluoromethoxy)-3-(trifluoromethyl)-1-methyl-1H-pyrazol-4-yl)methanol
EP1994035A1 (en) 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
BRPI0809147A2 (pt) 2007-03-23 2014-08-26 Basilea Pharmaceutica Ag Medicamentos combinados para tratamento de infecções bacterianas
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
EP2379546A1 (en) 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams

Also Published As

Publication number Publication date
EA027126B1 (ru) 2017-06-30
CO7101240A2 (es) 2014-10-31
AR089796A1 (es) 2014-09-17
AP2014007880A0 (en) 2014-08-31
HK1203389A1 (zh) 2015-10-30
PL2806873T3 (pl) 2016-12-30
CU20140090A7 (es) 2014-12-26
PH12014501671B1 (en) 2020-02-28
IN2014MN01640A (en:Method) 2015-05-22
KR102036393B1 (ko) 2019-10-24
CU24273B1 (es) 2017-08-08
CY1117955T1 (el) 2017-05-17
ECSP14010249A (es) 2015-12-31
EP2806873A1 (en) 2014-12-03
MY173843A (en) 2020-02-24
CL2014001956A1 (es) 2014-11-07
SI2806873T1 (sl) 2016-10-28
TW201343643A (zh) 2013-11-01
PE20142345A1 (es) 2015-01-09
AU2013211575B2 (en) 2017-03-02
UA110880C2 (uk) 2016-02-25
US20150045340A1 (en) 2015-02-12
SG11201403930XA (en) 2014-08-28
DK2806873T3 (en) 2016-08-29
BR112014017968A2 (en:Method) 2017-06-20
IL233805A0 (en) 2014-09-30
TN2014000297A1 (en) 2015-12-21
BR112014017968A8 (pt) 2017-07-11
ME02532B (me) 2017-02-20
NZ626951A (en) 2016-03-31
SMT201600354B (it) 2016-11-10
IL233805A (en) 2016-06-30
KR20140114390A (ko) 2014-09-26
ES2592403T3 (es) 2016-11-30
RS55210B1 (sr) 2017-01-31
PT2806873T (pt) 2016-09-23
TWI659953B (zh) 2019-05-21
JP5869701B2 (ja) 2016-02-24
CN104203237A (zh) 2014-12-10
MX346602B (es) 2017-03-24
MX2014008915A (es) 2014-08-26
LT2806873T (lt) 2016-10-10
CA2862338C (en) 2019-04-16
JP2015504907A (ja) 2015-02-16
PH12014501671A1 (en) 2014-11-10
US9556165B2 (en) 2017-01-31
ZA201405057B (en) 2017-09-27
US9782390B2 (en) 2017-10-10
HUE030452T2 (en) 2017-05-29
US20170100379A1 (en) 2017-04-13
CA2862338A1 (en) 2013-08-01
MA35905B1 (fr) 2014-12-01
EP2806873B1 (en) 2016-06-15
UY34585A (es) 2013-09-02
EA201400838A1 (ru) 2014-12-30
WO2013110643A1 (en) 2013-08-01
AU2013211575A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
HRP20161171T1 (hr) AMIDINSKI SUPSTITUIRANI β-LAKTAMSKI SPOJEVI, NJIHOVA PRIPRAVA I UPOTREBA KAO ANTIBAKTERIJSKIH SREDSTAVA
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
ES2569528T3 (es) 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
RU2348628C2 (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
JP2009518317A5 (en:Method)
RU2014142598A (ru) Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
PE20110063A1 (es) DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
HRP20110018T1 (hr) Derivati pirido(2,1-a)-izokinolina kao inhibitori dpp-iv
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
JP2002535323A5 (en:Method)
RU2000128036A (ru) Амидиновые соединения
JP2014506599A5 (en:Method)
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
SI3018132T1 (en) Condensed imidazole derivatives useful as IDO inhibitors
JP2017530185A5 (en:Method)
RU2009118602A (ru) Производное индола
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
SI2834239T1 (en) Heterobicyclic compounds as inhibitors of beta-lactamase
RU2010106854A (ru) Производные 2-аза-бицикло[3.3.0]октана
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
RU2019132254A (ru) Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP2014509600A5 (en:Method)
CA2522024A1 (en) Cgrp receptor antagonists